Furthermore, several studies have found that elevated pre-treatment NLR is associated with poor survival in early triple-negative BC patients (24) and progesterone receptor (PR)/estrogen receptor (ER) positive + human epidermal growth factor receptor 2 (HER2) negative BC patients (25), predicting poor response to NAC (26). This evidence concerns the gene ERBB2 and breast cancer.